Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DMAC vs EDIT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DMAC Captures Overall Composite Edge (46.3 HOLD vs 48.4 HOLD), While EDIT Leads 5–1 on Growth & Valuation Pillars
DMAC Overall Winner
6-Pillar Tally: DMAC 1 – 5 EDIT
Matrix Metrics: DMAC 6 – 2 EDIT
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (46.3/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality), while EDIT wins 5–1 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.41 (N/M Forward P/E, 0.0% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin).
- Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (6–2 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY).
- Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DMAC vs EDIT
DMAC
Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
$8.41
-4.27% 1D
Market Cap
$503.1M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.74β · 98% Vol
Unified Composite Score
46.3
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
EDIT
Editas Medicine, Inc. Common Stock
$1.91
-12.21% 1D
Market Cap
$336.5M
TTM Revenue
$50M
Forward P/E
N/M
Beta / 30D Vol
2.32β · 102% Vol
Unified Composite Score
48.4
HOLD
Tech 33.0
Fund 55.0
Flow 69.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (DMAC 1 – 5 EDIT)
1. Valuation Multiples
EDIT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
5.2x
2. Growth & Scale
EDIT
Revenue Growth (YoY)
+0.0%
+37.4%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$50M
Market Cap
$503.1M
$336.5M
3. Profitability & Quality
DMAC
Gross Margin
N/A
-73.3%
Operating Margin
0.0%
-167.0%
Net Profit Margin
0.0%
-144.9%
Return on Equity (ROE)
-114.6%
-147.4%
4. Balance Sheet & Cash Flow
EDIT
Cash Generation (TTM)
-$32M
-$110M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$4.9M Net Cash
$79M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
EDIT
Options Structure Phase
SURGE
BREAKDOWN
Current IV / %ile
106.3% (14th %ile)
95.8% (38th %ile)
Put/Call OI Skew
N/A
0.29x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
EDIT
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Concentrated Oligopoly Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DMAC (6) vs EDIT (2)| Institutional Metric | DMAC | EDIT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $503.1M | $336.5M | DMAC | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | +37.4% | EDIT | |
| Operating Margin (TTM) | 0.0% | -167.0% | DMAC | |
| Net Profit Margin | 0.0% | -144.9% | DMAC | |
| Return on Equity (ROE) | -114.6% | -147.4% | DMAC | |
| 52-Week Range Position | 55% ($5–$11) | 11% ($2–$4) | DMAC | |
| Beta / 30D Volatility | 1.74β · 98% Vol | 2.32β · 102% Vol | DMAC | |
| Unified Institutional Score | 46.3 / 100 (HOLD) | 48.4 / 100 (HOLD) | EDIT | |
| Trailing 12M Revenue (USD) | N/A | $50M | Scale | |
| Gross Profit Margin (TTM) | N/A | -73.3% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 5.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$32M ($4.9M Net Cash) | -$110M ($79M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DMAC +30.1 pp
3M Horizon
DMAC +61.16 pp
6M Horizon
DMAC +72.85 pp
1Y Horizon
DMAC +80.26 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | EDIT Revenue | DMAC Op. Margin | EDIT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $30M | -1352.2% | -356.1% | EDIT |
| FY2019 | N/A | $20M | N/A | -686.4% | EDIT |
| FY2020 | N/A | $90M | N/A | -148.6% | EDIT |
| FY2021 | N/A | $30M | N/A | -756.1% | EDIT |
| FY2022 | N/A | $20M | N/A | -1146.3% | EDIT |
| FY2023 | N/A | $80M | N/A | -216.6% | EDIT |
| FY2024 | N/A | $30M | N/A | -777.2% | EDIT |
| FY2025 | N/A | $40M | N/A | -394.9% | EDIT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DMAC
SURGE
Current IV
106.3%
IV Percentile
14th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
EDIT
BREAKDOWN
Current IV
95.8%
IV Percentile
38th %ile
Put/Call OI Skew
0.29x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact EDIT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DMAC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
EDIT Moat Profile
Concentrated Oligopoly Moat
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published · CRISPR / Gene Editing
Investor FAQ DMAC vs EDIT Key Questions & Quantitative Answers
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Editas Medicine, Inc. (EDIT) on higher Unified Composite conviction (46.3/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 6–2 (led by Profitability & Quality), while EDIT wins 5–1 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.41 (N/M Forward P/E, 0.0% operating margin) versus EDIT at $1.91 (N/M Forward P/E, -167.0% operating margin). Composite vs. Pillar Nuance: While EDIT currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (6–2 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -167.0% operating margin) and revenue trajectory (+0.0% vs. +37.4% YoY). Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7); meanwhile EDIT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EDIT leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EDIT at +37.4% YoY revenue growth and +0.0% YoY earnings growth on $50M TTM revenue (-73.3% gross margin, -167.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while EDIT shifted +33.3%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EDIT.
EDIT screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EDIT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus EDIT (-147.4% ROE) capital efficiency.
In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, EDIT carries 95.8% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
EDIT vs DMAC · Reverse Pair
DMAC vs TRVI
· Sector Peer
DMAC vs VRCA
· Sector Peer
DMAC vs FENC
· Sector Peer
EDIT vs NTLA
· Sector Peer
EDIT vs CRSP
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem